Genmab
Genmab to submit FDA application for lymphoma therapy
May 2, 2025Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …
AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn
June 11, 2020Research and Development AbbVie, Genmab, partnership, pharma
AbbVie has joined forces with Genmab to develop and commercialise three of the latter’s early-stage Genmab drug products – epcoritamab …
Genmab announces newly-created Chief Financial Officer appointment
March 16, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genmab, pharma
Genmab has announced the establishment of the new position of Chief Operating Officer at the company, and has furthermore named …
Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma
December 13, 2019Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma
The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …
European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma
November 20, 2019Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma
Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
Genmab’s Executive VP and CFO to retire in 2020
October 31, 2019Research and Development Genmab, appointment, pharma
David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …
FDA approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma
September 27, 2019Medical Communications, Sales and Marketing FDA, Genmab, darzalex, pharma
Genmab’s CD38 inhibitor Darzalex (daratumumab) has been awarded marketing authorisation from the FDA in combination with bortezomib, thalidomide and dexamethasone …
Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
September 3, 2019Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …
Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis
August 30, 2019Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma
Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma
May 8, 2018Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma
Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
J&J and Genmab’s drug races to second line treatment approval
November 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma
Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …
Gilead to work with Genmab on HIV targeting technology
August 12, 2016Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …
Darzalex receives breakthrough designation in multiple myeloma from FDA
July 26, 2016Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
